Vona Oncology

Executive Summary

Vona Oncology is a private, early-stage biopharmaceutical company headquartered in Cambridge, MA, focused on developing targeted small molecule therapeutics for aggressive cancers, including triple-negative breast cancer (TNBC), ovarian cancer, and melanoma. Founded in 2018, the company's lead candidate, VDX-431, is a small molecule drug targeting TNBC, a particularly aggressive subtype with limited treatment options. Despite being in the pre-clinical stage, the company holds potential due to its focus on high-need indications and a targeted approach. However, the lack of clinical data and public pipeline milestones introduces significant uncertainty. The company's valuation and total raised capital are undisclosed, indicating a nascent stage of development.

Upcoming Catalysts (preview)

• TBDIND Filing for VDX-43140% success
• TBDPreclinical Efficacy Data Update50% success
• TBDPartnership or Funding Announcement30% success